Daily Medication Pearl: Atogepant (Qulipta) for Episodic Migraine

Atogepant is indicated for the preventive treatment of episodic migraine in adults.

Medication Pearl of the Day: Atogepant (Qulipta)

Indication: Atogepant is a calcitonin gene-related peptide (CGRP) receptor antagonist indicated for the preventive treatment of episodic migraine in adults.

Insight:

  • Dosing: The recommended dosage is 10 mg, 30 mg, or 60 mg taken orally once daily with or without food. Severe renal impairment or end-stage renal disease take 10 mg once daily.
  • Dosage form: Tablets 10 mg, 30 mg, and 60 mg
  • Adverse events (AEs): The most common AEs (at least 4% and greater than placebo) are nausea, constipation, and fatigue.
  • Mechanism of action: Atogepant is a CGRP receptor antagonist.
  • Manufacturer: AbbVie

Sources:

Related Content:

RetailNeurologyMigraine
Pharmacists Play Essential Role in Addressing Health Care Disparities
FDA to Revise Labeling for Prescription Cough Medicine Following Overdose Concerns in Young Children
Study: HIV Infection Leaves ‘Memory’ in Cells, Resulting in Persistent Comorbidities